
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
urocortin III CRISPR/Cas9 KO Plasmid (h) | sc-406580 | 20 µg | $397.00 |
UCN3 encodes urocortin III, a secreted neuropeptide of the corticotropin-releasing factor family that preferentially signals through CRHR2 to modulate cAMP/PKA-dependent transcriptional programs. In neural and peripheral tissues, urocortin III contributes to regulation of stress-adaptive physiology, energy balance, and autonomic output, linking neuroendocrine cues to metabolic and cardiovascular homeostasis. CRHR2 pathway activity influenced by UCN3 has been studied in contexts of stress-related phenotypes, glucose handling, and vascular function, making UCN3 a useful node for dissecting peptide hormone signaling and receptor-selective CRF-family biology. Altered UCN3/CRHR2 signaling dynamics have been associated with neuroendocrine and metabolic dysregulation in experimental models, supporting its relevance for mechanistic disease research.
urocortin III CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the UCN3 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the UCN3 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the UCN3 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish urocortin III protein expression.
This CRISPR knockout system enables efficient generation of UCN3-deficient cell models for investigation of urocortin III signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
CRISPRs +/- HDRs
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.